- medical research
ZIRCON Phase III Kidney Cancer Imaging Study Completes Enrolment
MELBOURNE, Australia, July 11, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has dosed the final patient and completed recruitment into the Phase III pivotal study ZIRCON ( Zirconium in Renal Cancer Oncology, NCT03849118) of its investigational renal (kidney) cancer imaging agent TLX250-CDx ( 89Zr-DFO-girentuximab). This global study has dosed 300 patients to date, exceeding the...
Read more